BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu H, Mishra R, Yuan L, Abdul Salam SF, Liu J, Gray G, Sterling AD, Wunderlich M, Landero-Figueroa J, Garrett JT, Merino EJ. Oxidative Cyclization-Induced Activation of a Phosphoinositide 3-Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics. ChemMedChem 2019;14:1933-9. [PMID: 31696673 DOI: 10.1002/cmdc.201900481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Luo L, Zhong Q, Guo S, Zhang C, Zhang Q, Zheng S, He L, Wang G. Development of a bioavailable boron-containing PI-103 Bioisostere, PI-103BE. Bioorg Med Chem Lett 2020;30:127258. [PMID: 32527558 DOI: 10.1016/j.bmcl.2020.127258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Mishra R, Yuan L, Patel H, Karve AS, Zhu H, White A, Alanazi S, Desai P, Merino EJ, Garrett JT. Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. Int J Mol Sci 2021;22:2088. [PMID: 33669867 DOI: 10.3390/ijms22042088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. Int J Mol Sci 2021;22:3464. [PMID: 33801659 DOI: 10.3390/ijms22073464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]